Enovis (ENOV) Expected to Announce Earnings on Thursday

Key Points

• Enovis is scheduled to release its Q2 2025 earnings on August 7th, with analysts expecting $0.74 per share in earnings and $555.80 million in revenue.
• The company reported a positive earnings surprise in its last earnings release, posting $0.81 EPS against a consensus estimate of $0.74, along with revenue growth of 8.2% year-over-year.
• Institutional investors hold 98.45% of Enovis's stock, with significant increases in stakes from firms like Goldman Sachs, which boosted its position by 37.6% recently.

Enovis (NYSE:ENOV - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of $0.74 per share and revenue of $555.80 million for the quarter. Enovis has set its FY 2025 guidance at 2.950-3.100 EPS.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.81 EPS for the quarter, topping analysts' consensus estimates of $0.74 by $0.07. Enovis had a negative net margin of 37.65% and a positive return on equity of 5.99%. The firm had revenue of $558.83 million during the quarter, compared to analysts' expectations of $558.80 million. During the same period in the previous year, the business posted $0.50 earnings per share. The company's revenue for the quarter was up 8.2% compared to the same quarter last year. On average, analysts expect Enovis to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Enovis Stock Performance

Shares of NYSE:ENOV traded down $1.06 during trading on Friday, reaching $25.74. 1,336,017 shares of the stock were exchanged, compared to its average volume of 1,512,851. Enovis has a 12 month low of $25.70 and a 12 month high of $49.83. The stock has a 50-day moving average price of $31.04 and a 200-day moving average price of $35.91. The company has a current ratio of 2.55, a quick ratio of 1.32 and a debt-to-equity ratio of 0.52. The firm has a market cap of $1.47 billion, a PE ratio of -1.85 and a beta of 1.70.

Hedge Funds Weigh In On Enovis

Several institutional investors have recently made changes to their positions in the stock. Empowered Funds LLC raised its stake in Enovis by 13.0% during the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company's stock worth $249,000 after buying an additional 749 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Enovis by 37.6% during the first quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company's stock worth $10,226,000 after purchasing an additional 73,116 shares during the period. Finally, AQR Capital Management LLC lifted its holdings in shares of Enovis by 12.5% in the 1st quarter. AQR Capital Management LLC now owns 63,671 shares of the company's stock worth $2,363,000 after purchasing an additional 7,072 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on ENOV. Needham & Company LLC reduced their target price on Enovis from $64.00 to $57.00 and set a "buy" rating on the stock in a report on Friday, May 9th. JMP Securities reduced their price objective on shares of Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a research note on Friday, May 9th. Evercore ISI dropped their target price on shares of Enovis from $48.00 to $46.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Finally, Canaccord Genuity Group reduced their price target on shares of Enovis from $75.00 to $70.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $55.60.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.